JP2013538790A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013538790A5 JP2013538790A5 JP2013519111A JP2013519111A JP2013538790A5 JP 2013538790 A5 JP2013538790 A5 JP 2013538790A5 JP 2013519111 A JP2013519111 A JP 2013519111A JP 2013519111 A JP2013519111 A JP 2013519111A JP 2013538790 A5 JP2013538790 A5 JP 2013538790A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- lymphoma
- seq
- cell
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960000390 fludarabine Drugs 0.000 claims description 7
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims description 7
- 102000015098 Tumor Suppressor Protein p53 Human genes 0.000 claims description 6
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 claims description 6
- 238000012217 deletion Methods 0.000 claims description 5
- 230000037430 deletion Effects 0.000 claims description 5
- 230000004064 dysfunction Effects 0.000 claims description 5
- 229960004641 rituximab Drugs 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 24
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 claims 22
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 claims 22
- 238000000034 method Methods 0.000 claims 15
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 14
- 206010025323 Lymphomas Diseases 0.000 claims 12
- 210000003719 b-lymphocyte Anatomy 0.000 claims 11
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 10
- 208000003950 B-cell lymphoma Diseases 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 8
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 230000036210 malignancy Effects 0.000 claims 7
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 4
- 208000034578 Multiple myelomas Diseases 0.000 claims 4
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 4
- 208000032839 leukemia Diseases 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 claims 2
- 208000032568 B-cell prolymphocytic leukaemia Diseases 0.000 claims 2
- 208000023611 Burkitt leukaemia Diseases 0.000 claims 2
- 208000017604 Hodgkin disease Diseases 0.000 claims 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 2
- 201000003791 MALT lymphoma Diseases 0.000 claims 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 206010036711 Primary mediastinal large B-cell lymphomas Diseases 0.000 claims 2
- 208000035416 Prolymphocytic B-Cell Leukemia Diseases 0.000 claims 2
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 claims 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 2
- 230000005856 abnormality Effects 0.000 claims 2
- 210000001185 bone marrow Anatomy 0.000 claims 2
- 230000004663 cell proliferation Effects 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 201000006569 extramedullary plasmacytoma Diseases 0.000 claims 2
- 201000003444 follicular lymphoma Diseases 0.000 claims 2
- 201000009277 hairy cell leukemia Diseases 0.000 claims 2
- 230000002871 immunocytoma Effects 0.000 claims 2
- 208000026876 intravascular large B-cell lymphoma Diseases 0.000 claims 2
- 210000001165 lymph node Anatomy 0.000 claims 2
- 210000003563 lymphoid tissue Anatomy 0.000 claims 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims 2
- 210000004049 perilymph Anatomy 0.000 claims 2
- 208000016800 primary central nervous system lymphoma Diseases 0.000 claims 2
- 201000006576 solitary osseous plasmacytoma Diseases 0.000 claims 2
- 206010062113 splenic marginal zone lymphoma Diseases 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- 230000002950 deficient Effects 0.000 claims 1
- 230000000779 depleting effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 230000001589 lymphoproliferative effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 206010008805 Chromosomal abnormalities Diseases 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10169795 | 2010-07-16 | ||
| EP10169795.1 | 2010-07-16 | ||
| EP10175586 | 2010-09-07 | ||
| EP10175586.6 | 2010-09-07 | ||
| PCT/EP2011/062133 WO2012007576A1 (en) | 2010-07-16 | 2011-07-15 | Superior efficacy of cd37 antibodies in cll blood samples |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016148217A Division JP2017019800A (ja) | 2010-07-16 | 2016-07-28 | Ｃｌｌ血液サンプルにおけるｃｄ３７抗体の優れた効果 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013538790A JP2013538790A (ja) | 2013-10-17 |
| JP2013538790A5 true JP2013538790A5 (enExample) | 2015-12-24 |
Family
ID=44546328
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013519111A Pending JP2013538790A (ja) | 2010-07-16 | 2011-07-15 | Ｃｌｌ血液サンプルにおけるｃｄ３７抗体の優れた効果 |
| JP2016148217A Pending JP2017019800A (ja) | 2010-07-16 | 2016-07-28 | Ｃｌｌ血液サンプルにおけるｃｄ３７抗体の優れた効果 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016148217A Pending JP2017019800A (ja) | 2010-07-16 | 2016-07-28 | Ｃｌｌ血液サンプルにおけるｃｄ３７抗体の優れた効果 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20120189618A1 (enExample) |
| EP (2) | EP2593479A1 (enExample) |
| JP (2) | JP2013538790A (enExample) |
| KR (1) | KR20130100918A (enExample) |
| CN (2) | CN105749276A (enExample) |
| AU (1) | AU2011278227B2 (enExample) |
| BR (1) | BR112013001012A2 (enExample) |
| CA (1) | CA2799036A1 (enExample) |
| CL (1) | CL2013000101A1 (enExample) |
| EA (1) | EA025365B1 (enExample) |
| IL (1) | IL222775A (enExample) |
| MX (1) | MX341463B (enExample) |
| NZ (2) | NZ703225A (enExample) |
| PH (1) | PH12013500118A1 (enExample) |
| WO (1) | WO2012007576A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20120259A1 (es) * | 2007-08-09 | 2012-04-04 | Boehringer Ingelheim Int | Anticuerpos anti-cd37 |
| US20130287797A1 (en) * | 2012-04-26 | 2013-10-31 | Boehringer Ingelheim International Gmbh | Combination of cd37 antibodies with bendamustine |
| EP2849784A1 (en) | 2012-05-16 | 2015-03-25 | Boehringer Ingelheim International GmbH | Combination of cd37 antibodies with ice (ifosfamide, carboplatin, etoposide) |
| SG11201707089WA (en) * | 2015-04-13 | 2017-10-30 | Pfizer | Chimeric antigen receptors targeting b-cell maturation antigen |
| WO2018132506A1 (en) | 2017-01-10 | 2018-07-19 | The General Hospital Corporation | Chimeric antigen receptors based on alternative signal 1 domains |
| AU2018236450A1 (en) | 2017-03-16 | 2019-10-03 | The General Hospital Corporation | Chimeric antigen receptors targeting CD37 |
| UA127586C2 (uk) | 2017-03-31 | 2023-10-25 | Ґенмаб Холдінґ Б.В. | Біспецифічні анти-cd37-антитіла, моноклональні анти-cd37-антитіла та способи їх застосування |
| US12275797B2 (en) | 2018-06-22 | 2025-04-15 | Genmab Holding B.V. | Anti-CD37 antibodies and anti-CD20 antibodies, compositions and methods of use thereof |
| MA53812A (fr) | 2018-10-04 | 2021-08-11 | Genmab Holding B V | Compositions pharmaceutiques comprenant des anticorps anti-cd37 bispécifiques |
| EP4412715A1 (en) | 2021-10-06 | 2024-08-14 | Nordic Nanovector ASA | Humanized hh1 |
| WO2023057595A1 (en) | 2021-10-06 | 2023-04-13 | Nordic Nanovector Asa | Humanized hh1 rew |
| WO2025083205A1 (en) | 2023-10-18 | 2025-04-24 | Debiopharm International S.A. | Drug combination comprising anti-cd37 antibody maytansine conjugate and bcl2 inhibitor or pi3k inhibitor |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US20080279850A1 (en) * | 2005-07-25 | 2008-11-13 | Trubion Pharmaceuticals, Inc. | B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules |
| SG10201403526YA (en) * | 2005-07-25 | 2014-10-30 | Emergent Product Dev Seattle | B-cell reduction using cd37-specific and cd20-specific binding molecules |
| JP2010532764A (ja) * | 2007-07-06 | 2010-10-14 | トゥルビオン・ファーマシューティカルズ・インコーポレーテッド | Ｃ末端に配置された特異的結合性ドメインを有する結合性ペプチド |
| PE20120259A1 (es) * | 2007-08-09 | 2012-04-04 | Boehringer Ingelheim Int | Anticuerpos anti-cd37 |
| ES2368700T3 (es) * | 2008-04-11 | 2011-11-21 | Emergent Product Development Seattle, Llc | Agente inmunoterapéutico para cd37 y combinación con un agente quimioterapéutico bifuncional del mismo. |
| RU2526156C2 (ru) * | 2008-11-13 | 2014-08-20 | ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ, ЭлЭлСи | Cd37-иммунотерапевтическая комбинированная терапия и ее применения |
-
2011
- 2011-07-14 US US13/182,471 patent/US20120189618A1/en not_active Abandoned
- 2011-07-15 EP EP11732464.0A patent/EP2593479A1/en not_active Withdrawn
- 2011-07-15 JP JP2013519111A patent/JP2013538790A/ja active Pending
- 2011-07-15 EA EA201201660A patent/EA025365B1/ru not_active IP Right Cessation
- 2011-07-15 NZ NZ703225A patent/NZ703225A/en not_active IP Right Cessation
- 2011-07-15 CN CN201610095143.4A patent/CN105749276A/zh active Pending
- 2011-07-15 EP EP17174088.9A patent/EP3252077A1/en not_active Withdrawn
- 2011-07-15 CA CA2799036A patent/CA2799036A1/en not_active Abandoned
- 2011-07-15 WO PCT/EP2011/062133 patent/WO2012007576A1/en not_active Ceased
- 2011-07-15 PH PH1/2013/500118A patent/PH12013500118A1/en unknown
- 2011-07-15 KR KR1020127032811A patent/KR20130100918A/ko not_active Ceased
- 2011-07-15 MX MX2012013613A patent/MX341463B/es active IP Right Grant
- 2011-07-15 BR BR112013001012A patent/BR112013001012A2/pt not_active IP Right Cessation
- 2011-07-15 NZ NZ603161A patent/NZ603161A/en not_active IP Right Cessation
- 2011-07-15 CN CN2011800349727A patent/CN103003309A/zh active Pending
- 2011-07-15 AU AU2011278227A patent/AU2011278227B2/en not_active Ceased
-
2012
- 2012-10-31 IL IL222775A patent/IL222775A/en active IP Right Grant
-
2013
- 2013-01-10 CL CL2013000101A patent/CL2013000101A1/es unknown
- 2013-04-26 US US13/871,345 patent/US20130236454A1/en not_active Abandoned
-
2015
- 2015-04-13 US US14/684,928 patent/US20150266967A1/en not_active Abandoned
-
2016
- 2016-07-28 JP JP2016148217A patent/JP2017019800A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013538790A5 (enExample) | ||
| Moser-Katz et al. | Game of bones: how myeloma manipulates its microenvironment | |
| Wu et al. | T lymphocyte cell: a pivotal player in lung cancer | |
| Luo et al. | Necroptosis-dependent immunogenicity of cisplatin: implications for enhancing the radiation-induced abscopal effect | |
| US20190328838A1 (en) | Compositions comprising il-2 fusion proteins and methods for treating neoplasia | |
| MX2010005099A (es) | Usos de anticuerpos anti-cd40. | |
| CN118834840A (zh) | 嵌合痘病毒组合物及其用途 | |
| RU2017117664A (ru) | Комбинация | |
| JP2015517512A5 (enExample) | ||
| WO2007053661A3 (en) | Uses of anti-cd40 antibodies | |
| Smith et al. | PD-1 blockade following isolated limb perfusion with vaccinia virus prevents local and distant relapse of soft-tissue sarcoma | |
| WO2019230919A1 (ja) | 免疫チェックポイント阻害薬の有効性判定バイオマーカー | |
| PH12013500118A1 (en) | Superior efficacy of cd37 antibodies in cll blood samples | |
| JP2015517511A5 (enExample) | ||
| KR20210106531A (ko) | 암 치료를 위한 조성물 및 방법 | |
| EP4100030A1 (en) | Oncolytic virus compositions and methods for the treatment of cancer | |
| KR20220116438A (ko) | 암 치료를 위한 미생물총 및 대사산물의 힘 활용 | |
| Finocchiaro et al. | Hypermutations in gliomas: a potential immunotherapy target | |
| Vitiello et al. | Cisplatin and temozolomide combinatorial treatment triggers hypermutability and immune surveillance in experimental cancer models | |
| CY1118486T1 (el) | Λαπατινιμπη για τη θεραπεια του καρκινου | |
| CN110168089A (zh) | 抑制cd39表达的免疫抑制恢复寡核苷酸 | |
| CN113766955A (zh) | 对携带her2外显子21插入的癌细胞具有抗肿瘤活性的化合物 | |
| JP2019532635A (ja) | 腫瘍溶解性ウイルスを腫瘍に標的化する方法 | |
| WO2022094386A2 (en) | Tumor cell vaccines | |
| EP3593138A1 (en) | Compositions and methods for treating cancer with anti-renalase antibodies and anti-pd1 antibodies |